Text Size

Biodegradable intraocular therapies for retinal disorders: Progress to date

Kuno N., Fujii S.


  • 2010
  • Drugs and Aging
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Drug Delivery

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16, Takayama-cho, Ikoma-shi, Nara 630-0101, Japan

Related Publications

Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.


Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase 2/3 ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y. on behalf of the ORANGE study investigators


Epidemiology and burden of mild/moderate versus high myopia in Germany: A claims data analysis

Garcia TB, Kossack N, Pignot M, Dagher M, Schuster AK, Wielink KS.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022